🚀 Register to Join “Food Shouldn’t Hurt: EoE, Eupraxia, and a Promising New Treatment Approach” – (Friday, August 21 at 8:30am PT)

Tribe Public is welcoming James A. Helliwell, M.D., Co-Founder and Chief Executive Officer of Eupraxia Pharmaceuticals (NASDAQ: EPRX), for a timely discussion of Eupraxia’s work in EoE, its proprietary Diffusphere™ drug-delivery platform, and the potential opportunity ahead.

Dr. Helliwell brings an exceptional combination of clinical, scientific, entrepreneurial, and public-company leadership experience. A board-certified cardiac anesthesiologist, he previously practiced in cardiac transplantation and perioperative echocardiography, served as an Assistant Clinical Professor at the University of British Columbia, and held multiple leadership roles across academic medicine and business operations.

His belief that better outcomes can result from delivering “the right drug on target, on dose and on time” helped inspire the founding of Eupraxia. His work has appeared in leading journals including The Lancet Rheumatology, Gastroenterology, and Osteoarthritis & Cartilage. He is also a serial innovator, with eight granted patents and 35 pending patents across drug and device delivery.

Eupraxia is a clinical-stage biotechnology company developing locally delivered, extended-release products for areas of high unmet medical need. Its proprietary Diffusphere™ polymer-based microsphere technology is designed to support hyper-localized delivery and an extended duration of effect—an approach that could potentially reduce systemic exposure and avoid the peak-and-trough drug concentrations associated with more traditional delivery methods.

EoE is an inflammatory disease in which white blood cells build up in the esophagus, often causing pain and difficulty swallowing. More than 500,000 people in the United States are estimated to be affected, underscoring the importance of continued innovation in treatment approaches.

Join live

📅 Friday, August 21
⏰ 8:30 a.m. PT / 11:30 a.m. ET
🕒 Approximately 30 minutes, including a concise presentation and live 5–10 minute Q&A

Tribe Public events provide investors and consumers with direct access to corporate management teams and sector experts across industries. Our programs are designed to be informative, efficient, and accessible—whether you are joining from your office, home, or on the move.

If you are already registered, we look forward to seeing you live. If not, register today: Food Shouldn’t Hurt: EoE, Eupraxia, and a Promising New Treatment Approach

Have questions for Dr. Helliwell? Please send them in advance to research@tribepublic.com or submit them through the Zoom chat during the event.

Already signed up? Consider inviting a colleague, investor, healthcare professional, or friend who may be interested in learning more about EoE and precision drug delivery.